The individual survival benefits of tumor necrosis factor soluble receptor and fluid administration are not additive in a rat sepsis model

BACKGROUND: Tumor necrosis factor (TNF) antagonists [e.g., TNF soluble receptor (TNFsr)] improved survival in preclinical but not clinical sepsis trials. However fluid support—itself beneficial—is standard clinically but rarely employed in pre-clinical sepsis models. We hypothesized that these thera...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Qiu, Ping, Li, Yan, Ding, Yi, Weng, Jia, Banks, Steven M., Kern, Steven, Fitz, Yvonne, Suffredini, Anthony F., Eichacker, Peter Q., Cui, Xizhong
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3523295/
https://ncbi.nlm.nih.gov/pubmed/21922303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00134-011-2324-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky